TABLE 3.

Organ Involvement in Subjects with Systemic AL Amyloidosis: Active AL (n = 30) Versus Hematologic Remission of AL (n = 10)

	Visual		Quantitative		SUVmax
Organ	Active	Remission	Active	Remission	Active	Remission
Parotid	15 (50%)	5 (50%)	14 (47%)	5 (50%)	2.7 ± 1.6	2.7 ± 1.6
Tongue	13 (43%)	4 (40%)	15 (50%)	6 (60%)	2.9 ± 1.3	2.8 ± 1.5
Thyroid	6 (20%)	3 (30%)	9 (31%)	5 (50%)	3.3 ± 4.9	3.0 ± 2.3
Lung	9 (30%)	2 (20%)	11 (37%)	2 (20%)	2.2 ± 2.8	1.7 ± 2.0
Gastric wall	13 (43%)	0 (0%)	14 (47%)	1 (10%)	3.5 ± 2.9	1.9 ± 0.4
Pancreas	5 (17%)	0 (0%)	13 (43%)	3 (30%)	2.5 ± 0.8	2.1 ± 0.7
Kidney	4 (13%)	0 (0%)	5 (17%)	0 (0%)	2.2 ± 0.7*	1.7 ± 0.3
Spleen	8 (27%)	0 (0%)	7 (23%)	1 (10%)	2.7 ± 2.6	1.5 ± 1.7
Gluteal muscle	1 (3%)	0 (0%)	3 (10%)	0 (0%)	1.5 ± 0.6	1.3 ± 0.2
Abdominal wall fat	4 (13%)	0 (0%)	3 (10%)	0 (0%)	1.2 ± 0.8	1.2 ± 0.4
Humeral head	8 (27%)	0 (0%)	6 (20%)	0 (0%)	1.8 ± 0.9	1.2 ± 0.5

^*P = 0.0002.

Qualitative data are expressed as numbers followed by percentages in parentheses; continuous data are expressed as mean ± SD. Involved organs defined as SUV_max ≥ 2.5. Liver was considered unevaluable because of known hepatobiliary excretion of ¹⁸F-florbetapir.